Login to Your Account

Puma: Neratinib diarrhea fix loperamide gains cred in breast cancer phase II

By Randy Osborne
Staff Writer

Thursday, December 24, 2015

Puma Biotechnology Inc. last week took some of the edge off earlier findings about diarrhea with its late-stage cancer therapy neratinib when the company rolled out preliminary phase II results that show loperamide worked to lower the rates of the side effect in patients with HER2-positive breast cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription